Kalaris Therapeutics/$KLRS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kalaris Therapeutics
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
Ticker
$KLRS
Sector
Primary listing
Employees
14
Headquarters
Website
KLRS Metrics
BasicAdvanced
$47M
-
-$6.99
-
-
Price and volume
Market cap
$47M
52-week high
$12.90
52-week low
$2.14
Average daily volume
58K
Financial strength
Current ratio
11.979
Quick ratio
11.557
Interest coverage (TTM)
-1.60%
Profitability
Management effectiveness
Valuation
Price to book
0.88
Price to tangible book (TTM)
0.88
Price to free cash flow (TTM)
-0.911
Free cash flow yield (TTM)
-109.73%
Free cash flow per share (TTM)
-2.754
Growth
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kalaris Therapeutics stock?
Kalaris Therapeutics (KLRS) has a market cap of $47M as of August 26, 2025.
What is the P/E ratio for Kalaris Therapeutics stock?
The price to earnings (P/E) ratio for Kalaris Therapeutics (KLRS) stock is 0 as of August 26, 2025.
Does Kalaris Therapeutics stock pay dividends?
No, Kalaris Therapeutics (KLRS) stock does not pay dividends to its shareholders as of August 26, 2025.
When is the next Kalaris Therapeutics dividend payment date?
Kalaris Therapeutics (KLRS) stock does not pay dividends to its shareholders.
What is the beta indicator for Kalaris Therapeutics?
Kalaris Therapeutics (KLRS) does not currently have a Beta indicator.